Blog - Page 677 of 5690 - QualityStocks

FridayJul 21, 2023 11:22 am

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Participation in Water Tower Research Fireside Chat Series

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs. The company today announced that Jerry Griffin, VP of Sales and Marketing for InMed’s subsidiary BayMedica LLC, a leading supplier of bioidentical rare cannabinoids to the health and wellness (“H&W”) market, will be participating in a fireside chat with Water Tower Research on July 25, 2023, at 2:00 p.m. ET. The event is open for all investors with topics that include an overview of BayMedica, its competitive environment and upcoming catalysts, as well as the market dynamics of rare…

FridayJul 21, 2023 10:33 am

QualityStocksNewsBreaks – Lottery.com (NASDAQ: LTRY) Announces Funding Partner, Changes to Leadership Team

Lottery.com (NASDAQ: LTRY, LTRYW) today announced that United Capital Investments London, Ltd. (“UCIL”) has agreed to enter into a funding agreement with the company. The terms and conditions will be announced after the definitive agreement is finalized. The company also announced changes to its board of directors and executive management team that reflect its commitment to sustained growth and innovation in the gaming, sport and entertainment industries. “Lottery.com is committed to maintaining transparency, innovation and excellence in its operations and governance,” said Interim CEO and Chairman Matthew McGahan. “With the funding partner announced today and the board changes in place,…

FridayJul 21, 2023 10:01 am

QualityStocksNewsBreaks – First Tellurium Corp. (CSE: FTEL) (OTC: FSTTF) to Present Live at the Metals and Mining Virtual Investor Conference

First Tellurium (CSE: FTEL) (OTC: FSTTF) has announced that its president and CEO Tyrone Docherty will present live at the Metals and Mining Virtual Investor Conference, hosted by VirtualInvestorConferences.com, that is taking place on July 26 and 27, 2023. Docherty’s presentation is slated to begin at 11 a.m. PT on Wednesday, July 26. The company invites individual and institutional investors, as well as advisors and analysts, to attend in person or online at VirtualInvestorConferences.com. This will be a live, interactive online event where investors are invited to ask the company questions in real time. In addition, an archived webcast will…

FridayJul 21, 2023 9:45 am

Fintech Ecosystem Development Corp. (NASDAQ: FEXD) Continues to Support Cashless Society Technology by Meeting Mobile Money Needs Through Diverse Portfolio of Products and Services

Digital money is replacing physical cash and further supporting the growth of a growing cashless society driven by the pandemic and other factors FEXD supports the United Nations’ Sustainable Development Goals of reducing cross-border transaction costs from 7 percent to 3 percent FEXD plans to offer a diverse portfolio of products and services to consumers and businesses in the United States, South Asia, East Asia, Africa, Europe, and Latin America Financial technology, more commonly referred to as fintech, fuels economic growth and reduces inequality, poverty, and informality in underdeveloped companies. For impoverished people and small businesses without access to financial…

FridayJul 21, 2023 9:00 am

National GBM Awareness Events Underscore Significance of Clinical Trial Progress for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)

National awareness of glioblastoma tumors (“GBM”) sustained by Congressional leaders aim to improve efforts to treat brain cancers and ultimately improve patient survival GBM is a widely occurring, aggressive and effectively incurable brain cancer that few patients survive beyond three years U.S.-based drug developer CNS Pharmaceuticals is in the midst of a global potentially pivotal clinical trial for its lead pharmaceutical candidate, Berubicin, which it aims to show improves on standard of care chemotherapy agent Lomustine’s approach to treating GBM Berubicin is a novel anthracycline that is practically unique in its ability to cross the blood-brain barrier to directly target…

ThursdayJul 20, 2023 2:22 pm

QualityStocksNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Announces Deployment of K5 to One of Houston’s Most Historic Neighborhoods

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, has announced that Coppertree Village, a Houston area multi-family real estate community, deployed its first K5 ASR to enhance its security program and underscore the importance of public safety in a residential environment. Similar to positive results from the deployment by Las Vegas-based Liberty Village, the K5 will be helping to deter crime and loitering in an effort to create a safer and more secure community for resident families. The announcement reads, “Coppertree Village Apartments is a Fairstead owned and managed community centrally…

ThursdayJul 20, 2023 2:03 pm

QualityStocksNewsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Plans Launch Event to Celebrate Class 3 EV Production Milestone

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is planning a commercial EV launch event to commemorate a significant milestone: the first of its class 3 vehicles rolling off the production line. The event is slated for Aug. 24, 2023, and will be held at Mullen’s Mississippi-based commercial assembly plant. The company is planning factory tours and a company presentation as well as ride and drives and vehicle demonstrations. Event attendees will include media, customers, dealers, vehicle upfitters, suppliers and local leaders. The Mullen THREE is a class 3 low cab forward EV truck that has earned an…

ThursdayJul 20, 2023 1:10 pm

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Results from ‘Groundbreaking’ Sponsored Study Measuring Psychedelic Effects

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting on the release of study findings. Cybin sponsored the study, which was conducted by Kernel, a leader in noninvasive neuroimaging. Titled “Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS,” the study was published in “Scientific Reports from the Nature Portfolio of Journals” and evaluated the ability of Kernel’s Flow1 system to capture and analyze brain changes resulting from the administration of a psychoactive substance. According to the announcement, the single-blind, placebo-controlled…

ThursdayJul 20, 2023 12:36 pm

QualityStocksNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Announces Board Appointments of GBB Drink Lab Founder and President and Beverage Industry Veteran

Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness, today announced the appointment of John Gulyas to its board of directors and Rich Pascucci to its advisory board. Both Gulyas and Pascucci are formerly from GBB Drink Lab, creator of Safety Shot, the world’s first rapid blood alcohol detoxification drink recently acquired by Jupiter Wellness. “We are very pleased to have more of the stellar GBB Drink Lab team join Jupiter. John’s track record as a serial entrepreneur and innovator speaks for itself. With his passion, drive and know-how in moving Safety Shot from concept to market…

ThursdayJul 20, 2023 11:58 am

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Issues Update on BayMedica Rare Cannabinoid Business

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today provided a commercial and manufacturing update on its subsidiary BayMedica LLC, a leading supplier of bioidentical rare cannabinoids to the health and wellness (“H&W”) market. Among the highlights, the company reported a 123% quarter-over-quarter increase in revenues. “We are very encouraged to see another strong quarter with (unaudited) revenues in excess of $2.3M, representing our third consecutive quarter with significant revenue growth,” said Eric A. Adams, InMed’s president and CEO. “As demand for minor cannabinoids continues to increase, we…

Site Search

Company Search